Vir Biotechnology, Inc. (VIR)

Over the past six months, several events have influenced Vir Biotechnology's stock price. The company's stock trended down by 4.93% in the past six months and declined by 18.04% over the past year as of October 20, 2025. On May 7, 2025, Vir Biotechnology provided a corporate update and reported its first-quarter 2025 financial results. On May 28, 2025, the company participated in the Goldman Sachs 46th Annual Global Healthcare Conference. On August 6, 2025, Vir Biotechnology provided a corporate update and reported its second-quarter 2025 financial results. On August 27, 2025, BofA upgraded Vir Biotechnology to Buy from Neutral. On September 2, 2025, Director Sato Vicki L sold 22,000 shares of common stock. On September 9, 2025, the company participated in the Morgan Stanley 23rd Annual Global Healthcare Conference. On October 7, 2025, Vir Biotechnology announced it would present Week 48 SOLSTICE clinical results in Hepatitis Delta at AASLD's The Liver Meeting® 2025. On October 9, 2025, the company announced the first patient dosed in Part 3 of its Phase 1 trial of VIR-5500, leading to a 4.3% rise in stock. On October 22, 2025, Vir Biotechnology announced it would provide a corporate update and report third-quarter 2025 financial results on November 5, 2025. On October 27, 2025, updates were announced for ongoing Phase 3 clinical studies for chronic HDV treatment and a Phase 1 study for VIR-5500 in prostate cancer.

Demand seasonality for Vir Biotechnology's products and services is primarily linked to the nature of the infectious diseases they target. Influenza treatments are subject to seasonal demand, with flu season typically running from October through May. RSV also exhibits seasonality, with outbreaks generally occurring from fall to the end of spring. Treatments for chronic conditions like hepatitis B and hepatitis delta, and oncology treatments for solid tumors, are generally not subject to significant seasonal fluctuations in demand.

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on discovering and developing therapeutic products for serious infectious diseases and other severe conditions, including viral-associated diseases and solid tumors. The company leverages the immune system through technologies like antibodies, T cells, innate immunity, and siRNA. Its pipeline includes product candidates targeting conditions such as hepatitis B, influenza A, HIV, tuberculosis, hepatitis delta, COVID-19, RSV, HPV, and various solid tumors. Key pipeline products include tobevibart and elebsiran for hepatitis delta and hepatitis B, and VIR-5818, VIR-5500, and VIR-5525 for solid tumors. The company's revenue streams are derived from collaboration, contract, grant, and license revenues.

Vir Biotechnology's corporate office is located in San Francisco, California, and it maintains research activities at its sites in San Francisco and Bellinzona, Switzerland. In 2024, Vir Biotechnology closed its R&D facilities in St. Louis, Missouri, and Portland, Oregon, as part of a strategic effort to consolidate its geographic footprint and optimize its cost structure.

Vir Biotechnology's brand reputation in the past year appears to be generally positive, driven by advancements in its clinical pipeline. The company's media sentiment score is 0.37, with an average medical news sentiment of 0.71, indicating a leaning towards positive press. Recent news coverage has highlighted promising developments, such as the initiation of Phase 3 studies for HDV treatment and Phase 1 studies for oncology candidates. An analyst upgrade to "Buy" also reflects a positive perception of the company's potential. Customer reviews for ChemoMetec's cell counting instruments, which Vir Biotechnology uses, describe the products as reliable, reproducible, easy to use, and fast.

As of October 22, 2025, institutional investors hold approximately 59% ownership in Vir Biotechnology. Major institutional holders include BlackRock, Inc., SB Investment Advisers (UK) Limited, and The Vanguard Group, Inc. Individual insiders own approximately 4.4% of the shares, while public companies and individual investors hold a combined 19.76% to 48.63% of the stock.